Literature DB >> 27536366

Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis.

Andrea Tenca1, Martti Färkkilä2, Johanna Arola3, Tytti Jaakkola4, Roberto Penagini5, Kaija-Leena Kolho4.   

Abstract

BACKGROUND: The natural history of pediatric-onset primary sclerosing cholangitis (PSC) and overlap with autoimmune hepatitis (PSC/AIH) is poorly known.
OBJECTIVE: The aim of this study was to evaluate the clinical outcome of patients with pediatric-onset disease in a tertiary referral center.
METHODS: We traced 33 patients (median age at diagnosis 16 years), with PSC or PSC/AIH in cholangiography and liver histology diagnosed between December 1993 and 2011, at Helsinki University Hospital. Diagnostic procedures and long-term follow-up were reassessed until the end of December 2013.
RESULTS: PSC was confirmed in all 33 patients; 19 of them had an overlap with AIH. At diagnosis, three of 33 had cirrhosis. Inflammatory bowel disease (IBD) was associated in 76% of the patients, mostly ulcerative colitis (70%); treatment of IBD being a minor determinant of the clinical outcome of liver disease. In the last follow-up (median nine years), all patients were alive, and no malignancy occurred. Most patients (91%) were on ursodeoxycholic acid and 12 PSC/AIH patients on immunosuppression. Endoscopic retrograde cholangiography during follow-up showed a progression of intra-hepatic disease in 12 patients (36%). Four patients (12%) had undergone liver transplantation, and one was listed; no recurrence of the disease in the graft was seen.
CONCLUSION: The clinical course and outcome of pediatric-onset PSC and PSC/AIH seem to be favourable in the majority of patients until early adulthood. In about one-third of patients, however, PSC is progressive, challenging the current treatment guidelines and warranting further studies on disease pathogenesis.

Entities:  

Keywords:  Pediatric; cirrhosis; inflammatory bowel disease; liver transplantation; primary sclerosing cholangitis

Year:  2015        PMID: 27536366      PMCID: PMC4971785          DOI: 10.1177/2050640615616012

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  26 in total

1.  Validation of a cholangiographic prognostic model in primary sclerosing cholangitis.

Authors:  C Y Ponsioen; J B Reitsma; K M Boberg; L Aabakken; E A Rauws; E Schrumpf
Journal:  Endoscopy       Date:  2010-07-09       Impact factor: 10.093

2.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

3.  Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.

Authors:  Espen Melum; Andre Franke; Christoph Schramm; Tobias J Weismüller; Daniel Nils Gotthardt; Felix A Offner; Brian D Juran; Jon K Laerdahl; Verena Labi; Einar Björnsson; Rinse K Weersma; Liesbet Henckaerts; Andreas Teufel; Christian Rust; Eva Ellinghaus; Tobias Balschun; Kirsten Muri Boberg; David Ellinghaus; Annika Bergquist; Peter Sauer; Euijung Ryu; Johannes Roksund Hov; Jochen Wedemeyer; Björn Lindkvist; Michael Wittig; Robert J Porte; Kristian Holm; Christian Gieger; H-Erich Wichmann; Pieter Stokkers; Cyriel Y Ponsioen; Heiko Runz; Adolf Stiehl; Cisca Wijmenga; Martina Sterneck; Severine Vermeire; Ulrich Beuers; Andreas Villunger; Erik Schrumpf; Konstantinos N Lazaridis; Michael P Manns; Stefan Schreiber; Tom H Karlsen
Journal:  Nat Genet       Date:  2010-12-12       Impact factor: 38.330

4.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

5.  Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma.

Authors:  Emily G Barr Fritcher; Benjamin R Kipp; Jesse S Voss; Amy C Clayton; Keith D Lindor; Kevin C Halling; Gregory J Gores
Journal:  Am J Gastroenterol       Date:  2011-08-16       Impact factor: 10.864

6.  Complications of ERCP: a prospective study.

Authors:  Merete Christensen; Peter Matzen; Svend Schulze; Jacob Rosenberg
Journal:  Gastrointest Endosc       Date:  2004-11       Impact factor: 9.427

7.  Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years.

Authors:  Peter B Cotton; Donald A Garrow; Joseph Gallagher; Joseph Romagnuolo
Journal:  Gastrointest Endosc       Date:  2009-03-14       Impact factor: 9.427

8.  Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history.

Authors:  Mark Deneau; M Kyle Jensen; John Holmen; Marc S Williams; Linda S Book; Stephen L Guthery
Journal:  Hepatology       Date:  2013-08-13       Impact factor: 17.425

9.  Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.

Authors:  Yinka K Davies; Kathleen M Cox; Bisher A Abdullah; Anca Safta; Annie B Terry; Kenneth L Cox
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-07       Impact factor: 2.839

10.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

View more
  2 in total

Review 1.  Cholangitis: Diagnosis, Treatment and Prognosis.

Authors:  Amir Houshang Mohammad Alizadeh
Journal:  J Clin Transl Hepatol       Date:  2017-09-07

Review 2.  Autoimmune hepatitis: current challenges and future prospects.

Authors:  Yoshio Aizawa; Atsushi Hokari
Journal:  Clin Exp Gastroenterol       Date:  2017-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.